Dr. Parikh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2011 - 2014
Ascension Illinois/Saint FrancisResidency, Internal Medicine, 2002 - 2005
Seth G.S. Medical CollegeClass of 2001
Certifications & Licensure
MN State Medical License 2010 - 2025
TX State Medical License 2005 - 2011
IL State Medical License 2002 - 2005
Clinical Trials
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2018 Sep 10
- A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome Start of enrollment: 2017 Mar 08
Roles: Contact
Publications & Presentations
PubMed
- 21 citationsChronic lymphocytic leukemia treatment algorithm 2022.Paul J Hampel, Sameer A Parikh
Blood Cancer Journal. 2022-11-29 - 48 citationsValidation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.Massimo Gentile, Tait D. Shanafelt, Davide Rossi, Luca Laurenti, Francesca Romana Mauro
Blood. 2016-10-20 - 177 citationsPortal Vein ThrombosisSameer Parikh, Riddhi Shah, Prashant Kapoor
The American Journal of Medicine. 2010-02-01
Journal Articles
- Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical CentreSameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology
Abstracts/Posters
- Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple MyelomaSameer A. Parikh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)Sameer A. Parikh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition is Mechanistically Supported By a Novel Direct Interaction of G...Sameer A. Parikh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Case 1: Newly Diagnosed CLL, IGHV-UnmutatedJanuary 28th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
